Fig. 2From: Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERSShown are the event rates per 100 patient years for the composite endpoints a target lesion failure and b major adverse cardiac events for both treatment groups (red and blue bars). In addition, the 95% confidence intervals are also presented (red and blue brackets). No significant differences were found between both treatment groups. TLF target lesion failure, CI confidence interval, EE-BRS everolimus-eluting bioresorbable scaffolds, EES everolimus-eluting stents, MACE major adverse cardiac eventsBack to article page